HYUNDAI FEED Inc Total Liabilities
HYUNDAI FEED Inc total liabilities. Based on the latest financial reports, HYUNDAI FEED Inc (016790) has total liabilities worth ₩28.17 Billion KRW (≈ $19.09 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 016790 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of HYUNDAI FEED Inc (2015–2024)
Total liabilities of HYUNDAI FEED Inc from 2015 to 2024. This chart illustrates how HYUNDAI FEED Inc's total liabilities have evolved over time, based on quarterly financial data. Explore HYUNDAI FEED Inc (016790) long-term investment share to see how much of total assets are deployed in long-term investments.
HYUNDAI FEED Inc Competitors by Total Liabilities
The table below lists competitors of HYUNDAI FEED Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dekpol SA
WAR:DEK
|
Poland | zł1.25 Billion |
|
CCK Consolidated Holdings Bhd
KLSE:7035
|
Malaysia | RM127.48 Million |
|
Gatekeeper Systems Inc
V:GSI
|
Canada | CA$4.21 Million |
|
Shandong Molong Petroleum Machinery Company Limited
F:PXI
|
Germany | €1.82 Billion |
|
Aurum Resources Ltd
AU:AUE
|
Australia | AU$3.03 Million |
|
Informa PLC
LSE:INF
|
UK | GBX6.69 Billion |
|
Business Online PCL
BK:BOL
|
Thailand | ฿453.29 Million |
|
Huangshan Tourism Development Co Ltd B
SHG:900942
|
China | $1.00 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down HYUNDAI FEED Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 016790 total asset value.
Liquidity & Leverage Metrics
HYUNDAI FEED Inc Total Liabilities Ratios Explained
HYUNDAI FEED Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how HYUNDAI FEED Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for HYUNDAI FEED Inc (2015–2024)
The table below shows the annual total liabilities of HYUNDAI FEED Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩28.05 Billion ≈ $19.01 Million |
-84.47% |
| 2023-12-31 | ₩180.58 Billion ≈ $122.38 Million |
-21.11% |
| 2022-12-31 | ₩228.90 Billion ≈ $155.12 Million |
+533.27% |
| 2021-12-31 | ₩36.15 Billion ≈ $24.50 Million |
-7.88% |
| 2020-12-31 | ₩39.24 Billion ≈ $26.59 Million |
+3.47% |
| 2019-12-31 | ₩37.92 Billion ≈ $25.70 Million |
+1.87% |
| 2018-12-31 | ₩37.23 Billion ≈ $25.23 Million |
+3.12% |
| 2017-12-31 | ₩36.10 Billion ≈ $24.46 Million |
-5.78% |
| 2016-12-31 | ₩38.31 Billion ≈ $25.97 Million |
-41.07% |
| 2015-12-31 | ₩65.02 Billion ≈ $44.06 Million |
-- |
About HYUNDAI FEED Inc
HYUNDAI FEED Inc. engages in the manufacture and sale of formulated feed. Its primary products include poultry and pig feed. The company also engages in the biopharmaceutical business. In addition, it focuses on the development and commercialization of immunotherapies for cancer. Further, the company's lead product includes oregovomab, an immunotherapy for ovarian cancer. Additionally, it is invo… Read more